Fatigue News and Research

RSS

Gene linked to lupus might explain gender difference in disease risk

In an international human genetic study, researchers at UT Southwestern Medical Center have identified a gene linked to the autoimmune disease lupus, and its location on the X chromosome might help explain why females are 10 times more susceptible to the disease than males.

30 Mar 2009

Gene linked to lupus might explain why females are 10 times more susceptible to the disease

30 Mar 2009

Dapagliflozin trial results indicate improvement in key glycemic measures in treatment-naive type 2 diabetes

Findings published in Diabetes Care from a 12-week, Phase IIb dose-ranging study showed that dapagliflozin, a novel, selective, sodium glucose co-transporter2 (SGLT2) inhibitor, produced clinically meaningful reductions across all key glycemic measures studied [glycosylated hemoglobin level (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG)] in treatment-naive type 2 diabetes patients, compared to placebo.

29 Mar 2009

Protein from tick saliva shows potential for myasthenia gravis treatment

Looking for a better treatment for the autoimmune disease myasthenia gravis, researchers have found that a protein in tick saliva shows promise in limiting the severity of the disease in an animal model in a study published in the Annals of Neurology.

29 Mar 2009

Rexahn Pharmaceuticals starts phase II pancreatic cancer trial

Rexahn Pharmaceuticals, Inc. has announced that it has received FDA approval to begin Phase II trials for Archexin, the Company's leading cancer compound, for the treatment of pancreatic cancer.

24 Mar 2009

FDA approves new indication for Wyeth's Tygacil (tigecycline)

Wyeth Pharmaceuticals, a division of Wyeth has announced that the U.S. Food and Drug Administration (FDA) approved Tygacil (tigecycline), for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens.

24 Mar 2009

FDA approves Symbyax for treatment-resistant depression

The U.S. Food and Drug Administration (FDA) has approved a new indication for Symbyax (olanzapine and fluoxetine HCl capsules), Eli Lilly and Company has announced.

23 Mar 2009

Gulf War veterans display abnormal brain response to specific chemicals

A new study by UT Southwestern Medical Center researchers is the first to pinpoint damage inside the brains of veterans suffering from Gulf War syndrome - a finding that links the illness to chemical exposures and may lead to diagnostic tests and treatments.

22 Mar 2009

Powerful antioxidant found in a tiny plant reduce computer eye strain

Along with the computer age comes the age of eye fatigue. As we sit for endless hours staring at our computer (whether at work or leisure), we develop a host of symptoms and resulting complaints. Burning achy eyes, headache, blurry vision, stiff shoulders ... sound familiar? Well, you are not alone.

20 Mar 2009

Gleevec reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors

Data published online and in an upcoming print issue of The Lancet show that Gleevec (imatinib mesylate) tablets, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.

20 Mar 2009

Experimental vaccine shows promise in preventing cytomegalovirus infection

Each year, approximately 8,000 infants in the United States develop severe hearing, mental or movement impairments after becoming infected with cytomegalovirus (CMV), a common virus passed onto them while still in the womb.

19 Mar 2009

Happy pills in America -- Our complex love affair with designer consciousness

The spectacular increase in the use of psychiatric drugs over the past 50 years involved what a University at Buffalo historian calls "a massive break with what we consider 'normal' mental health," one linked to myriad social and cultural changes in America.

19 Mar 2009

New data on link between cancer and nutrition

European experts in cancer and nutrition are meeting in Zurich, Switzerland late this month to discuss cutting-edge research in one of the most important and fiercely debated topics in cancer prevention: the link between diet and cancer.

12 Mar 2009

Research shed new light on anergia

With the help of a non-invasive method of monitoring human activity, doctors and researchers at Columbia University Medical Center are shedding new light on a syndrome affecting nearly 40 percent of older adults with heart failure: anergia.

11 Mar 2009

Mandatory obstructive sleep apnea screenings could reduce risk of truck crashes

Truck crashes are a significant public health hazard causing thousands of deaths and injuries each year, with driver fatigue and sleepiness being major causes.

11 Mar 2009

10 million people in the U.S. suffer from lower-limb peripheral arterial disease

According to iData Research, an international medical device & dental market research firm, an estimated 10 million people in the U.S. suffer from lower-limb Peripheral Arterial Disease (PAD), with less than 20% of these diagnosed by a physician.

11 Mar 2009

First 'nano' treatments to target cancer cells

Cancer Research UK scientists have for the first time developed a treatment that transports 'tumour busting' genes selectively to cancer cells, according to a study published online in Cancer Research.

11 Mar 2009

European Commission and US FDA approve intravenous formulation of temozolomide

Schering-Plough Corporation (NYSE:SGP) today announced that the European Commission and the US FDA both approved the intravenous (IV) formulation of temozolomide as an alternative to the already approved oral form of the drug.

5 Mar 2009

Positive emotions critical for upkeep of physical health for people worldwide

A researcher from the University of Kansas has spearheaded a new investigation into the link between emotions and health.

4 Mar 2009

Measuring quality of life in patients with hereditary kidney disease

A commonly used questionnaire that measures quality of life is not sensitive enough to pick up mental and physical problems experienced by patients with autosomal dominant polycystic kidney disease (ADPKD), according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

4 Mar 2009